Skip to main
CYRX
CYRX logo

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort Inc is positioned for growth as the increasing acceptance of cell and gene therapies is anticipated to lead to a steady rise in both commercial revenue and clinical trial activity. Additionally, the company has seen a consistent increase in gene therapy programs across various stages, particularly in oncology and rare diseases, indicating a burgeoning pipeline of approved therapies. This positive market trend, combined with CryoPort's integral role in the life sciences supply chain across multiple global regions, supports a favorable outlook for its financial performance.

Bears say

CryoPort Inc. is experiencing a negative outlook primarily due to a continuous decline in start-up funding within the life sciences sector, particularly affecting Series A and seed funding, suggesting a tighter capital environment for companies in this space. Additionally, APCA is facing a notable slowdown in demand for MVE freezers, indicating challenges in product sales and potential revenue decline year-over-year. This combination of reduced funding and weaker demand highlights significant headwinds that could adversely impact CryoPort's financial performance moving forward.

CryoPort (CYRX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Buy based on their latest research and market trends.

According to 9 analysts, CryoPort (CYRX) has a Buy consensus rating as of Nov 7, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.